Abstract: The invention relates to selected difluoro compounds of formulae Ia, Ib and Ic ( set out hereinafter) which are useful as inhibitors of human leukocyte elastase.
Abstract: A method for the separation or purification of biopolymers comprises adsorbing the biopolymer on the surface of liquid oil droplets; and separating the adsorbed biopolymer from the oil droplets. The adsorbed biopolymer is separated from the oil droplets by mixing the droplets in an aqueous liquid, removing the lower aqueous phase and adding a fresh aqueous phase to the droplets, cooling the mixture to solidify and coalesce the oil and to cause it to release the adsorbed biopolymer to the fresh liquid, separating the fresh liquid and the biopolymer from the coalesced oil, separating the biopolymer from the fresh liquid.
Abstract: Novel amino acid derivatives useful as a therapeutic agent are disclosed. These amino acid derivatives and the pharmaceutically acceptable salts thereof have a human renin inhibitory effect when administered orally and are useful for treatment of hypertension, especially renin-associated hypertension.
Abstract: A method of increasing the modulus of elasticity of a biopolymer is disclosed, which comprises incorporating a hexameric unit of the formula--X--(APGVGV).sub.n --Y--whereinA is a peptide-forming residue of L-alanine;P is a peptide-forming residue of L-proline;G is a peptide-forming residue of glycine;V is a peptide-forming residue of L-valine;X is PGVGV, GVGV, VGV, GV, V, or a covalent bond;Y is APGVG, APGV, APG, AP, A, or a covalent bond; andn is an integer from 2 to 200, wherein said hexameric unit comprises at least 18 amino acid residues, into an elastomeric polypeptide chain.
Abstract: This invention relates to a pharmaceuticals which contains thyroid hormones and improved method which extracts thyroid hormones from animal thyroid gland. The pharmaceuticals of this invention is used to treat senile cortical cataract. There are some effect of long term on other cataract except subcapsular cataract. The pharmaceuticals of this invention is applied in the form of eyedrops or injection.
Type:
Grant
Filed:
June 12, 1987
Date of Patent:
September 26, 1989
Assignee:
The Hospital Attached to Tianjin Academy of Medical Sciences
Abstract: A method of treating osteoporosis, especially post-menopausal osteoporosis, by administering on a periodic but regular basis to a patient growth hormone releasing factor, GRF(1-44)-NH.sub.2, or a biologically active analog thereof, and continuing the administration until bone mass increases and the patient's calcium balance becomes positive and indicates a mineral accumulation in the skeleton.
Abstract: Substantially pure, synthetic peptides corresponding to specific epitopic sites of various G-proteins and antibodies having binding affinity specifically for said epitopic sites have been prepared. Kit and method for identifying various G-proteins are also disclosed.
Type:
Grant
Filed:
September 25, 1987
Date of Patent:
September 26, 1989
Assignee:
The United States of America as represented by the Department of Health and Human Services
Abstract: Acylated cyanamide compounds useful for ethanol deterrence of the formula RCONHCN, wherein R is a lipophilic acyl group or is derived from an (N-substituted)-alpha-aminoacyl group.
Abstract: A composition which can bind heparin and promote cellular adhesion is provided which consists essentially of a polypeptide of the formula:arg-tyr-val-leu-pro-arg-This invention was made with Government support under contract number CA 29995 by the U.S.The Government has certain rights in the invention.
Abstract: A peptide that causes a suppression in protein synthesis by halting the translation of mRNA into protein, the peptide having a Stokes radius of less than 16 Angstroms, a molecular weight, determined by SDS-PAGE, of 17 kD (indicating that the peptide is a monomer) and an isoelectric point of 7.25. The peptide of the present invention may have therapeutic advantages in halting the proliferation of abnormal or excess protein,GOVERNMENT RIGHTSThis invention was made with United States Government support under Grant HL 24511-06 from the NIH. The United States Government has certain rights in this invention.
Abstract: Peptides comprising, in sequence, units selected from the amino acid residues 17 to 24 of VIP, and consisting at least of the amino acid residues 18 to 23, or an analogue thereof wherein one or more of the amino acid residues is replaced by an equivalent other amino acid; having anti-ulcer activity, a process for their preparation and their use as pharmaceuticals.
Type:
Grant
Filed:
October 17, 1986
Date of Patent:
September 12, 1989
Assignee:
Beecham Group p.l.c.
Inventors:
Gordon Wootton, Eric A. Watts, Christine Summers
Abstract: A method for stimulating integumental melanocytes by the topical application of alpha-MSH analogs, and compositions comprising said analogs for use in the method are described.
Type:
Grant
Filed:
July 22, 1988
Date of Patent:
September 12, 1989
Assignee:
University Patents, Inc.
Inventors:
Victor J. Hruby, Mac E. Hadley, Robert Dorr, Norman Levine, Elizabeth Sugg, Wayne L. Cody
Abstract: Macromolecular monoclonal antibody compositions are provided which are capable of selectively forming stable bonds to cells having a predetermined concentration of at least one surface antigen, such concentration being greater in such cells than in other cells in the cell population, wherein the composition comprises a substrate and a plurality of monoclonal antibodies specific to said surface antigen or antigens, which antibodies are covalently bonded to the substrate.
Type:
Grant
Filed:
October 10, 1986
Date of Patent:
September 5, 1989
Assignee:
Linus Pauling Institute of Science and Medicine
Abstract: The invention concerns novel renin-inhibiting peptides which are modified as isosteres. These peptides are useful for treating renin-associated hypertension and hyperaldosteronism. Processes for preparing the peptides, compositions containing them and methods for using them are included. Also included is a diagnostic test using the peptides to determine the presence of renin-associated hypertension or hyperaldosteronism.
Type:
Grant
Filed:
February 4, 1987
Date of Patent:
September 5, 1989
Assignee:
Warner-Lambert Company
Inventors:
James P. Hudspeth, James S. Kaltenbronn, Joseph T. Repine, Peter W. K. Woo
Abstract: Novel biologically active polypeptides, including a new class of transforming growth factor (TGF) polypeptides, which exhibit cell growth promoting properties are disclosed, as well as a process for isolating the TGF polypeptides from both human and murine cell lines in homogeneous form. Also disclosed are antigenic oligopeptides derived from the TGF polypeptides and antibodies raised therefrom which have application in the detection and treatment of malignancies and oligipeptides which have the ability to bind with cellular growth factor receptors and thus to interfere with transformation of certain cell lines into a cancerous state. Compositions and methods based on the disclosed peptides for detection and treatment of cancer and other proliferative diseases and for cell or tissue growth associated treatment, e.g., wound healing, ulcer therapy and bone loss are also described.
Abstract: The present invention provides novel renin-inhibiting peptides of the formula X-A.sub.6 -B.sub.7 -C.sub.8 -D.sub.9 -E.sub.10 -F.sub.11 -G.sub.12 -H.sub.13 - I.sub.14 -Z, wherein the E.sub.10 -F.sub.11 moiety is a dihydroxyethylene isostere, X and Z are terminal groups, and the remaining variables are absent or are amino acid residues. Such inhibitors are useful for the control of hypertension.
Abstract: Antitumor effect of antitumor agents or treatments is favorably controlled by a growth factor. The growth factor enhances antitumor actions of antitumor agents or treatments including those against which tumor or cancer has acquired resistant, or reduces side effects due to the antitumor agents or treatments. The most typical growth factors include human epidermal growth factor. A lot of tumors or cancers including human ones has been tested and a lot of growth factors has been tested, and the favorable control has been determined.
Type:
Grant
Filed:
November 28, 1986
Date of Patent:
September 5, 1989
Assignee:
Wakunaga Seiyaku Kabushiki Kaisha
Inventors:
Harunobu Amagase, Masato Arakawa, Ken Hashimoto
Abstract: The invention relates to new peptides of the formula ##STR1## in which X, A, B, C, N', E, F, G and Z have the meanings indicated in the description, to a process for their preparation, to agents containing them, and to their use.
Type:
Grant
Filed:
January 14, 1987
Date of Patent:
August 29, 1989
Assignee:
Hoechst Aktiengesellschaft
Inventors:
Gerhard Breipohl, Jochen Knolle, Wolfgang Konig, Bernward Scholkens
Abstract: Certain polypeptide-phospholipid complexes consisting of the amphipathic, helical portion of human apo A and its analogs and a phospholipid are useful in the treatment of neonatal respiratory distress syndrome.